Global Anti-Obesity Prescription Drugs Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global Anti-Obesity Prescription Drugs market size will reach Million USD in 2025 and is projected to reach Million USD by 2032, with a CAGR of % (2025-2032). Notably, the China Anti-Obesity Prescription Drugs market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Anti-obesity prescription drugs are medications that are prescribed by doctors to people who are obese or overweight in order to help them lose weight by suppressing the appetite or reducing the absorption of fat in the body. These drugs work by changing the way the body processes food and nutrients, and may also cause changes in metabolism and energy levels. Some common anti-obesity prescription drugs include phentermine, liraglutide, orlistat, and Belviq. These drugs are typically used in combination with diet and exercise to achieve maximum weight loss results.
The major global suppliers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Anti-Obesity Prescription Drugs. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Anti-Obesity Prescription Drugs market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Anti-Obesity Prescription Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Anti-Obesity Prescription Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Anti-Obesity Prescription Drugs Include:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Anti-Obesity Prescription Drugs Product Segment Include:
Pediatric
Adult
Anti-Obesity Prescription Drugs Product Application Include:
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Anti-Obesity Prescription Drugs Industry PESTEL Analysis
Chapter 3: Global Anti-Obesity Prescription Drugs Industry Porter's Five Forces Analysis
Chapter 4: Global Anti-Obesity Prescription Drugs Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Anti-Obesity Prescription Drugs Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Anti-Obesity Prescription Drugs Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Anti-Obesity Prescription Drugs Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global Anti-Obesity Prescription Drugs market size will reach Million USD in 2025 and is projected to reach Million USD by 2032, with a CAGR of % (2025-2032). Notably, the China Anti-Obesity Prescription Drugs market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Anti-obesity prescription drugs are medications that are prescribed by doctors to people who are obese or overweight in order to help them lose weight by suppressing the appetite or reducing the absorption of fat in the body. These drugs work by changing the way the body processes food and nutrients, and may also cause changes in metabolism and energy levels. Some common anti-obesity prescription drugs include phentermine, liraglutide, orlistat, and Belviq. These drugs are typically used in combination with diet and exercise to achieve maximum weight loss results.
The major global suppliers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim, Alizyme, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Anti-Obesity Prescription Drugs. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Anti-Obesity Prescription Drugs market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Anti-Obesity Prescription Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Anti-Obesity Prescription Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Anti-Obesity Prescription Drugs Include:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Anti-Obesity Prescription Drugs Product Segment Include:
Pediatric
Adult
Anti-Obesity Prescription Drugs Product Application Include:
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Anti-Obesity Prescription Drugs Industry PESTEL Analysis
Chapter 3: Global Anti-Obesity Prescription Drugs Industry Porter's Five Forces Analysis
Chapter 4: Global Anti-Obesity Prescription Drugs Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Anti-Obesity Prescription Drugs Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Anti-Obesity Prescription Drugs Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Anti-Obesity Prescription Drugs Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Anti-Obesity Prescription Drugs Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Anti-Obesity Prescription Drugs Product by Type
- 1.2.1 Pediatric
- 1.2.2 Adult
- 1.3 Anti-Obesity Prescription Drugs Product by Application
- 1.3.1 Hospitals Pharmacies
- 1.3.2 Retail Pharmacies
- 1.3.3 E-commerce
- 1.4 Global Anti-Obesity Prescription Drugs Market Size Analysis (2020-2032)
- 1.5 Anti-Obesity Prescription Drugs Market Development Status and Trends
- 1.5.1 Anti-Obesity Prescription Drugs Industry Development Status Analysis
- 1.5.2 Anti-Obesity Prescription Drugs Industry Development Trends Analysis
- 2 Anti-Obesity Prescription Drugs Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Anti-Obesity Prescription Drugs Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Anti-Obesity Prescription Drugs Market Analysis by Country
- 4.1 Global Anti-Obesity Prescription Drugs Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Anti-Obesity Prescription Drugs Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Anti-Obesity Prescription Drugs Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.5 China Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.6 France Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.14 India Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Anti-Obesity Prescription Drugs Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Anti-Obesity Prescription Drugs Market Revenue by Key Suppliers (2021-2025)
- 5.2 Anti-Obesity Prescription Drugs Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Anti-Obesity Prescription Drugs Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Anti-Obesity Prescription Drugs Market Analysis by Type
- 6.1 Global Anti-Obesity Prescription Drugs Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Anti-Obesity Prescription Drugs Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 F Hoffmann La Roche Ltd
- 7.1.1 F Hoffmann La Roche Ltd Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
- 7.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Orexigen Therapeutics
- 7.2.1 Orexigen Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
- 7.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Novo Nordisk A/s
- 7.3.1 Novo Nordisk A/s Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
- 7.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Arena Pharmaceuticals
- 7.4.1 Arena Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
- 7.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Glaxosmithkline
- 7.5.1 Glaxosmithkline Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
- 7.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Vivus
- 7.6.1 Vivus Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Vivus Anti-Obesity Prescription Drugs Product Portfolio
- 7.6.3 Vivus Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Boehringer Ingelheim
- 7.7.1 Boehringer Ingelheim Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
- 7.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Alizyme
- 7.8.1 Alizyme Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
- 7.8.3 Alizyme Anti-Obesity Prescription Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Anti-Obesity Prescription Drugs Industry Chain Analysis
- 8.2 Anti-Obesity Prescription Drugs Product Downstream Application Analysis
- 8.2.1 Global Anti-Obesity Prescription Drugs Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Anti-Obesity Prescription Drugs Revenue and Forecast by Application (2020-2032)
- 8.3 Anti-Obesity Prescription Drugs Typical Downstream Customers
- 8.4 Anti-Obesity Prescription Drugs Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
